Non-mutagenic impurities
Supporting the assessment and control of your non-mutagenic impurities and contaminants
Assessment and control of non-mutagenic impurities and contaminants
Why choose Consult Lhasa?
Consult Lhasa provide expert risk assessments for non-mutagenic impurities and cross contaminants, built on Lhasa Limited science, that can be trusted by industry and regulatory authorities.
If you need assistance with your non-mutagenic impurity risk assessment, Consult Lhasa.
How can our experts help you to assess
non-mutagenic impurities?
Do you need help establishing safe limits for your non-genotoxic impurities (NGIs)?
When a non-genotoxic impurity (NGI) is present above the qualification threshold, an impurity qualification becomes necessary. We can provide a weight of evidence assessment to determine a safe limit for your NGI.
Does your process involve a residual solvent not included in ICH Q3C?
If a solvent is not included within the ICH Q3C guidelines, an independent calculation is required to determine an acceptable intake. If relevant and robust data exists, we can perform a permitted daily exposure (PDE) risk assessment to establish an acceptable limit for your residual solvent.
What if there is insufficient data for your solvent, not included in ICH Q3C?
In cases where high-quality data for your residual solvent is unavailable, the correct analogue – or class of analogues – needs to be identified. Where possible, we will provide appropriate read-across analogues and utilise the anologue/s to establish an acceptable intake (AI) for your residual solvent.
Do you need help evaluating the level of elemental impurities in your final drug product?
Elemental impurities (EIs) can originate from several sources and need to be controlled to a safe limit. It is important to evaluate each source to understand its contribution to overall EI levels in the final drug product. We can help you to assess the risk of EIs in your final drug product, relative to the permitted daily exposure (PDE), in line with the ICH Q3D guidance. If necessary, based on the risk assessment outcome, we can propose a control strategy.
Do you need support defining health based exposure limits?
When multiple medicinal products are manufactured in a shared facility, the risk of cross-contamination should be evaluated. We can provide a structured scientific evaluation of pharmacological and toxicological data to define a health based exposure limit for your product, considering the other products manufactured within the facility. The outcome will be a threshold value e.g. permitted daily exposure (PDE) or threshold of toxicological concern (TTC) .
We provide regulatory support
ICH Q3A
ICH Q3B
ICH Q3C
ICH Q3D
“Our experience with Consult Lhasa has been very positive, resulting in a final report that we are confident will meet the scope required by regulatory agencies. The Consult Lhasa team are knowledgeable about the regulatory needs of the region, particularly Brazil, and provide great support. Their consulting has been invaluable to our company, the technical, scientific and human exchange has been impeccable. We are very satisfied with the collaboration.”
Adriana Tomalino, Head of Regulatory Affairs at Triquim
“We recently had the experience of collaborating with Consult Lhasa to address an EU regulatory deficiency on a potential degradation impurity of the drug substance. Consult Lhasa made an intriguing task look simple in the final report which was based on Zeneth, literature review and expert analysis. Their professionalism and commitment to excellence were truly commendable and their proactive approach made the entire process seamless and ensured that we met the stringent regulatory timelines. Their core scientific knowledge, hands-on experience with the pharmaceutical industry and caliber of their work make them a standout choice. It is evident that they take great pride in what they do, and this pride reflects in the exceptional quality of their work. We strongly recommend Consult Lhasa to anyone seeking expert advice on API degradation profile, drug-excipient compatibility, leachables & extractables, potentially mutagenic and non-mutagenic impurities and most importantly the nitrosamine impurities.”
Muzaffar Khan, Senior General Manager within Regulatory Affairs at Laurus Labs Limited
Get in touch
If you are interested in discovering how Consult Lhasa could improve your non-mutagenic impurities risk assessments, get in touch.